Do you base your decision on extent of residual disease?
Does the use of preoperative immunotherapy have an impact on surgical site size or hea...
New answer by Medical Oncologist at The Ohio State University Comprehensive Cancer Center / James Cancer Hospital and Solove Research Institute (January 17, 2026)
I would continue cemiplimab adjuvantly (not pembrolizumab adjuvantly, as the KEYNOTE-630 trial was negative), if patients' post-resection path showed high-risk features for re...